Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1
Xin Zhang, Qian Hao, Wenyue Yang, Yunbo Yu, Qingya Yan, Zhenhua Wu, Zhihuang Hu, Xiang Zhou, Jialei Wang · 2026
Read Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1 by Xin Zhang, Qian Hao, Wenyue Yang, Yunbo Yu, Qingya Yan, Zhenhua Wu, Zhihuang Hu, Xiang Zhou, Jialei Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13564959.txt.
Description
Zhang and coauthors probe why some lung tumors respond well to immune care. A gene pair found in some lung tumors marks that good response. One gene, KRAS, drives tumor growth in these cases. The other gene, p53, is changed from its normal form.
The team traced the link to a protein called SPP1. Changed p53 works with a partner to shut SPP1 down. KRAS, by contrast, turns SPP1 up through a growth path. Low SPP1 means fewer suppressor cells reach the tumor. With fewer such cells, immune care can attack the tumor more freely. The work names SPP1 as a key switch in this response.
Catalog record
| CREATOR | Xin Zhang, Qian Hao, Wenyue Yang, Yunbo Yu, Qingya Yan, Zhenhua Wu, Zhihuang Hu, Xiang Zhou, Jialei Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |